These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17627670)

  • 1. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
    Greenberg WM; Citrome L
    CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
    Stimmel GL; Gutierrez MA; Lee V
    Clin Ther; 2002 Jan; 24(1):21-37. PubMed ID: 11833834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone, a new atypical antipsychotic drug.
    Carnahan RM; Lund BC; Perry PJ
    Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
    Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
    CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug safety evaluation of ziprasidone.
    Citrome L
    Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone in the treatment of affective disorders: a review.
    Rosa AR; Franco C; Torrent C; Comes M; Cruz N; Horga G; Benabarre A; Vieta E
    CNS Neurosci Ther; 2008; 14(4):278-86. PubMed ID: 19040553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of intramuscular ziprasidone in the management of acute psychotic agitation.
    Mendelowitz AJ
    Ann Clin Psychiatry; 2004; 16(3):145-54. PubMed ID: 15517847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best clinical practice with ziprasidone IM: update after 2 years of experience.
    Zimbroff DL; Allen MH; Battaglia J; Citrome L; Fishkind A; Francis A; Herr DL; Hughes D; Martel M; Preval H; Ross R
    CNS Spectr; 2005 Sep; 10(9):1-15. PubMed ID: 16247923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
    Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
    Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.